123 related articles for article (PubMed ID: 17725246)
1. Effects of sympatholytic therapy on insulin sensitivity indices in hypertensive postmenopausal women.
Kaaja R; Kujala S; Manhem K; Katzman P; Kibarskis A; Antikainen R; Ylihärsilä H; Erkkola R; Tuomilehto J
Int J Clin Pharmacol Ther; 2007 Jul; 45(7):394-401. PubMed ID: 17725246
[TBL] [Abstract][Full Text] [Related]
2. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist.
Kaaja R; Manhem K; Tuomilehto J
Int J Clin Pract Suppl; 2004 Mar; (139):26-32. PubMed ID: 15117110
[TBL] [Abstract][Full Text] [Related]
3. Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women.
Kujala SM; Pöyhönen-Alho M; Kaaja RJ
Climacteric; 2014 Aug; 17(4):356-62. PubMed ID: 24099152
[TBL] [Abstract][Full Text] [Related]
4. Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women.
Pöyhönen-Alho MK; Manhem K; Katzman P; Kibarskis A; Antikainen RL; Erkkola RU; Tuomilehto JO; Ebeling PE; Kaaja RJ
J Hypertens; 2008 Dec; 26(12):2445-9. PubMed ID: 19008724
[TBL] [Abstract][Full Text] [Related]
5. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.
Haenni A; Lithell H
J Hypertens Suppl; 1999 Aug; 17(3):S29-35. PubMed ID: 10489096
[TBL] [Abstract][Full Text] [Related]
6. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.
Giugliano D; Acampora R; Marfella R; De Rosa N; Ziccardi P; Ragone R; De Angelis L; D'Onofrio F
Ann Intern Med; 1997 Jun; 126(12):955-9. PubMed ID: 9182472
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.
Reid JL; Panfilov V; MacPhee G; Elliott HL
Ann N Y Acad Sci; 1995 Jul; 763():673-8. PubMed ID: 7677387
[TBL] [Abstract][Full Text] [Related]
8. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
[TBL] [Abstract][Full Text] [Related]
9. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients.
Poirier L; Cléroux J; Nadeau A; Lacourcière Y
J Hypertens; 2001 Aug; 19(8):1429-35. PubMed ID: 11518851
[TBL] [Abstract][Full Text] [Related]
10. Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial.
Masajtis-Zagajewska A; Majer J; Nowicki M
Hypertens Res; 2010 Apr; 33(4):348-53. PubMed ID: 20139920
[TBL] [Abstract][Full Text] [Related]
11. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
Chazova I; Almazov VA; Shlyakhto E
Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
[TBL] [Abstract][Full Text] [Related]
12. Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women.
Ebinç H; Ozkurt ZN; Ebinç FA; Ucardag D; Caglayan O; Yilmaz M
J Int Med Res; 2008; 36(1):80-7. PubMed ID: 18230271
[TBL] [Abstract][Full Text] [Related]
13. Insulin sensitivity following treatment with the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol in hypertensive non-insulin-dependent diabetes mellitus patients.
Eriksson JW; Jansson PA; Foley K; Lithell H
J Hypertens; 1996 Dec; 14(12):1469-75. PubMed ID: 8986932
[TBL] [Abstract][Full Text] [Related]
14. Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: A randomized, double-blind, controlled study of 21 obese hypertensives.
Kuperstein R; Sasson Z
Circulation; 2000 Oct; 102(15):1802-6. PubMed ID: 11023935
[TBL] [Abstract][Full Text] [Related]
15. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes.
Jacob S; Klimm HJ; Rett K; Helsberg K; Häring HU; Gödicke J
Exp Clin Endocrinol Diabetes; 2004 Jun; 112(6):315-22. PubMed ID: 15216449
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients.
Deftereos S; Giannopoulos G; Kossyvakis C; Efremidis M; Panagopoulou V; Raisakis K; Kaoukis A; Karageorgiou S; Bouras G; Katsivas A; Pyrgakis V; Stefanadis C
Am J Cardiol; 2013 Sep; 112(5):684-7. PubMed ID: 23726175
[TBL] [Abstract][Full Text] [Related]
17. Selective imidazoline agonist moxonidine in obese hypertensive patients.
Sanjuliani AF; de Abreu VG; Francischetti EA
Int J Clin Pract; 2006 May; 60(5):621-9. PubMed ID: 16700870
[TBL] [Abstract][Full Text] [Related]
18. Considerations in the treatment of insulin resistance and related disorders with a new sympatholytic agent.
Lithell HO
J Hypertens Suppl; 1997 Jan; 15(1):S39-42. PubMed ID: 9050984
[TBL] [Abstract][Full Text] [Related]
19. Effect of bunazosin and atenolol on glucose metabolism in obese, nondiabetic patients with primary hypertension.
Bönner G; Schmieder R; Chrosch R; Weidinger G
Cardiovasc Drugs Ther; 1997 Mar; 11(1):21-6. PubMed ID: 9140673
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
Prichard BN; Owens CW; Graham BR
J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
